ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 191 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,651,779 | -75.1% | 79,260 | -71.4% | 0.01% | -75.0% |
| Q2 2023 | $6,638,845 | -47.9% | 277,196 | -59.0% | 0.02% | -55.6% |
| Q1 2023 | $12,737,225 | -16.3% | 676,792 | -29.2% | 0.04% | -18.2% |
| Q4 2022 | $15,214,553 | +3914.4% | 955,688 | +4022.0% | 0.06% | +2650.0% |
| Q3 2022 | $379,000 | -19.4% | 23,185 | +19.3% | 0.00% | 0.0% |
| Q1 2022 | $470,000 | -82.5% | 19,436 | -61.2% | 0.00% | -83.3% |
| Q4 2020 | $2,680,000 | +9.7% | 50,129 | -15.4% | 0.01% | +20.0% |
| Q3 2020 | $2,444,000 | -56.3% | 59,260 | -48.7% | 0.01% | -64.3% |
| Q2 2020 | $5,594,000 | +167.0% | 115,420 | +132.8% | 0.03% | +100.0% |
| Q1 2020 | $2,095,000 | -43.9% | 49,585 | -43.2% | 0.01% | +16.7% |
| Q4 2019 | $3,735,000 | +188.6% | 87,317 | +81.1% | 0.01% | +140.0% |
| Q1 2019 | $1,294,000 | +60.5% | 48,215 | -3.3% | 0.01% | +25.0% |
| Q4 2018 | $806,000 | +467.6% | 49,861 | +689.7% | 0.00% | +300.0% |
| Q1 2018 | $142,000 | – | 6,314 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| March Altus Capital Management LP | 82,723 | $2,685,000 | 20.75% |
| HWG Holdings LP | 289,380 | $9,393,000 | 8.72% |
| Baker Brothers Advisors | 24,516,738 | $795,813,000 | 8.34% |
| HARVEY CAPITAL MANAGEMENT INC | 352,200 | $11,432,000 | 5.73% |
| Belmont Global Advisors, Inc. | 150,000 | $4,869,000 | 4.67% |
| Palo Alto Investors LP | 1,437,730 | $46,669,000 | 3.52% |
| Avoro Capital Advisors LLC | 329,500 | $10,696,000 | 2.38% |
| GARRISON BRADFORD & ASSOCIATES INC | 70,100 | $2,275,000 | 2.23% |
| WEATHERBIE CAPITAL, LLC | 401,642 | $13,037,000 | 1.85% |
| ACUTA CAPITAL PARTNERS, LLC | 85,999 | $2,792,000 | 1.34% |